Drug
Atn 103 Q4wks
Atn 103 Q4wks: highest development phase Phase 1/2, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| ATN-103 10 mg q4wks NCT01007175 | Phase 1/2 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Atn 103 Q4wks on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.